Q4 2024 Earnings Call Transcript March 12, 2025 OptimizeRx Corporation beats earnings expectations. Reported EPS is $0.3, ...

OptimizeRx reports sales of $32.32M in Q4, beating consensus, with adjusted EPS of $0.30. Full-year revenue increased 29% and ...

Full Year 2024 Results Key Financial Results Revenue: US$92.1m (up 29% from FY 2023).

Q4 revenue of $32.3 million, increasing 14% year-over-yearQ4 gross profit increased 23% year-over-year to $22.0 million with gross margin of ...

Roth MKM reiterates a Buy rating on OptimizeRx (OPRX) with a $16 price target following the Q4 report. The company reported “strong” results ...

Stephen Silvestro; President, Chief Executive Officer; OPTIMIZERx Corp. Edward Stelmakh; Chief Financial Officer, Chief Operating Officer; OPTIMIZERx Corp. Andrew D' ...

OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.26 per share a year ago. These ...

This article was originally published on Quiver News, read the full story. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of ...

Q4 2024 Results Conference Call March 12, 2025 8:30 AM ETCompany ParticipantsSteve Silvestro - PresidentEdward ...

OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.26 per share a year ago.

March 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage ...

Stephen L. Silvestro, OptimizeRx CEO commented, "I'm incredibly proud of our strong fourth quarter and full year 2024 results and the momentum that we've achieved since we reported third quarter ...